Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
about
Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disordersRetargeting the management of hypercholesterolemia - focus on evolocumabEconomic Evaluation of PCSK9 Inhibitors in Reducing Cardiovascular Risk from Health System and Private Payer Perspectives.Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease.Cholesterol Management in the Era of PCSK9 Inhibitors.Modelling the cost-effectiveness PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.High-density Lipoprotein and Low-density Lipoprotein Therapeutic Approaches in Acute Coronary Syndromes.Association of Prior Authorization and Out-of-pocket Costs With Patient Access to PCSK9 Inhibitor Therapy.Limitations of traditional health technology assessment methods and implications for the evaluation of novel therapies.Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.Prediction of cardiovascular risk in patients with familial hypercholesterolaemia.Cost-effectiveness of evolocumab in treatment of heterozygous familial hypercholesterolaemia in Bulgaria: measuring health benefit by effectively treated patient-years.'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies.Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.PCSK9 inhibitor valuation: A science-based review of the two recent models.Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD).
P2860
Q28070296-A7140ACA-FDFF-4CF1-A8A8-C3D94F074BC2Q28077289-46DB9289-CF83-4DF0-91A7-53535C3A80F2Q36247530-3232E7B6-B4A7-4A04-9875-D97BF9C4B70AQ38612448-8B9F668D-92BA-4D10-81DE-895E5E16C6A6Q38639580-89D59CBE-4D00-4F10-A5FE-922915FE1C86Q38690757-46A7CDE1-099D-4686-A4FE-B9AE9841F302Q38965138-EA81D321-6178-48E6-906F-B5E06D4F5E9EQ46077572-20494F01-76F0-4363-A594-13A54A585206Q46505421-E72D2712-E5B3-4FA5-B1C4-74891D135DC6Q47392228-55DA13AD-A871-4C06-982D-36B2D6C304F7Q47643635-4FF784F6-C883-49BE-B5CC-B8E55E7CADF6Q48520042-0F85B8BD-A68C-44F2-9C8E-F92393D418B5Q48570562-839F8B8F-F11C-4569-9EF1-F6711D9A15A6Q51329562-9D02828A-15AA-4E7C-94DA-2BB61217ED30Q52364662-03B2FDAA-A445-4959-9BBF-02B01A345AA7Q55476982-9F0B3CA0-0F6A-45E7-8E2B-7006F3E989CE
P2860
Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 April 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@en
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@nl
type
label
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@en
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@nl
prefLabel
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@en
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@nl
P2093
P2860
P356
P1433
P1476
Cost-Effectiveness of LDL-C Lo ...... lar Risk in the United States.
@en
P2093
Ben van Hout
Guillermo Villa
Mickael Lothgren
Peter Lindgren
Ransi Somaratne
Shravanthi R Gandra
P2860
P304
P356
10.1002/CLC.22535
P577
2016-04-19T00:00:00Z